Posted by Michael Wonder on 11 Feb 2020
SMC - February 2020 decisions
10 February 2020 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today published advice on six new medicines.
Assessment reports have been published for two medicines to treat extremely rare conditions, voretigene neparvovec (Luxturna) and burosumab (Crysvita).
These are the first medicines to be assessed within the ultra-orphan pathway - a new approach introduced earlier this year.
